Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.

× No keyword cloud information.

11 in total

1. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.

Authors: Blanca Sanchez-Gonzalez; Jose C Pascual-Ramirez; Pascual Fernandez-Abellan; Isabel Belinchon-Romero; Concepcion Rivas; Gloria Vegara-Aguilera
Journal: Blood Date: 2003-03-15 Impact factor: 22.113

2. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Authors: S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz
Journal: Blood Date: 2005-08-23 Impact factor: 22.113

3. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.

Authors: Baijun Fang; Yongping Song; Jie Ma; Robert C Zhao
Journal: Acta Haematol Date: 2007-05-15 Impact factor: 2.195

4. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.

Authors: Carmen P Castaneda; Nancy A Brandenburg; Robert Bwire; Graham H Burton; Jerome B Zeldis
Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544

5. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.

Authors: Hans P Sviggum; Mark D P Davis; S Vincent Rajkumar; Angela Dispenzieri
Journal: Arch Dermatol Date: 2006-10

6. Stevens-Johnson syndrome after treatment with rituximab.

Authors: S Lowndes; A Darby; G Mead; A Lister
Journal: Ann Oncol Date: 2002-12 Impact factor: 32.976

7. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors: Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal: Arch Dermatol Date: 2002-08

8. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors: J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal: N Engl J Med Date: 1995-12-14 Impact factor: 91.245

9. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors: Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal: J Invest Dermatol Date: 2007-09-06 Impact factor: 8.551

Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.